Modern Chinese Medicine Group Co., Ltd. (“MODERN CHI MED”) has dispatched its circular and notice of annual general meeting (AGM) to be held on 29 May 2026 in Shijiazhuang, Hebei. Key resolutions are summarized below:

• Share Repurchase Mandate – Directors seek authority to buy back up to 72.00 million shares, equal to 10% of the current issued share capital of 720.00 million shares.

• Share Issuance Mandate – Directors request a general mandate to allot and issue up to 144.00 million new shares, representing 20% of existing issued shares, with an extension to add repurchased shares to the issuance limit.

• Board Composition – Executive Chair Sun Xinlei and independent non-executive director Liu Ling will retire by rotation and stand for re-election. Sun, via Modern Biotechnology Group Holdings, controls 402.00 million shares (55.83% stake).

• Articles of Association – A special resolution will adopt a fully restated set of articles enhancing electronic communication, permitting hybrid/virtual meetings and modernizing governance language.

• Other Items – The AGM will also consider re-appointing Forvis Mazars CPA Limited as auditor, authorising directors to set remuneration, and approving ordinary dividends when applicable.

Key Timetable • Share register closure: 26 – 29 May 2026 (both days inclusive). • Proxy deadline: 27 May 2026, 10:00 a.m. • AGM: 29 May 2026, 10:00 a.m.

Implementation of the mandates would give the board flexibility for capital management while maintaining the minimum public float. Any buy-back or issuance would remain subject to Hong Kong Listing Rules and Cayman Islands law.